Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analyses. ^[1]
• Redemplo (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
• Inclisiran in hypercholesterolemia showed a 44.09% reduction in low-density lipoprotein (LDL) and a 37.5% reduction in apolipoprotein levels. Lepodisiran and olpasiran in hyperlipoproteinemia(a) achieved a 75.69% drop in apolipoproteins and a 16.25% reduction in LDL.
• Arrowhead apolipoprotein C-III (ARO-APOC3) and plozasiran in hypertriglyceridemia produced over 50% reductions in very-low-density lipoprotein (VLDL) and triglycerides. Plozasiran in mixed hyperlipidemia and chylomicronemia reduced triglycerides by up to 79% and apolipoproteins by 87.5%.
• Comparative findings indicate similar over 50% VLDL and triglyceride reductions for plozasiran and ARO-APOC3 in hypertriglyceridemia, while plozasiran showed greater triglyceride and apolipoprotein reductions than inclisiran, lepodisiran, and olpasiran within their respective populations.
• Across the studies, reported adverse effects included nasopharyngitis (NP), diabetes mellitus (new-onset and worsening), injection site adverse effects (ISRs), back pain, and hypertension.
• There are no population types or subgroups information available in the reviewed studies.